U.S. Markets closed

PetVivo Holdings, Inc. (PETV)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7400-0.0800 (-9.76%)
At close: 3:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8200
Open0.7350
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7250 - 0.8199
52 Week Range0.1220 - 1.0000
Volume5,857
Avg. Volume6,409
Market Cap17.178M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-0.1090
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    PETVIVO HOLDINGS, INC. HIRES DR. DAVID B MASTERS AS DIRECTOR OF SCIENCE AND TECHNOLOGY

    MINNEAPOLIS, Sept. 10, 2020 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Dr. David B. Masters has extended his role with the company as its new Director of Science and Technology. "We are very happy to have Dr. Masters greatly extend his efforts and provide his well-recognized expertise to further the overall mission of PetVivo.” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Dr. Masters brings a wealth of knowhow experience to our product development and manufacturing team, not only as the creator/inventor of our base biomaterial and our therapeutic products, but also as an expert and innovator in the field of biomaterial science and regenerative medicine. Technology powers our strategy, and Dr. Masters’ proven leadership dramatically drives such a strategy to increase PetVivo’s enterprise value. As CEO/CTO of Gel-Del Technologies and as a principal investigator at Harvard Medical School and the Mayo Clinic, his efforts produced National Institutes of Health (NIH) awards totaling over six million dollars. Dr. Masters will extensively reinforce and advance our goals, thereby making PetVivo a leader in medical device technology and further enhancing the health and wellness of our pets."As the Director of Science and Technology, Dr. Masters will lead teams throughout PetVivo’s Technology Group to refine the development of new commercial products and work hand in hand with the manufacturing team and licensing-partners to mass produce therapeutic products for global commercialization. Such efforts will include streamlining our technology development and commercial manufacturing processes for PetVivo’s vast toolbox of products, thereby enabling company growth through a strong competitive product pipeline."I am incredibly excited about increasing my efforts with PetVivo’s management team and participating in the journey to commercialize its proprietary product, Kush®, for the treatment of osteoarthritis, as well as advancing our revolutionary mucoadhesive drug and nutritional supplement delivery systems” said Dr. Masters. "My focus is always on making sure PetVivo’s product pipeline is realized through exceptionally functioning prototypes and perfected manufacturing procedures that lead to successful commercial products and beneficial licensing partnerships.”PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of eighteen patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs and horses called Kush® is scheduled for launch later this fiscal year.The Company recently exclusively licensed its mucoadhesive technology to a strategic partner, Emerald Organic Products, Inc., for use of CBD in the human nutraceutical market. The Company will also be seeking additional licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.(All Press Releases Will Be Available for Viewing on the Web at www.petvivo.com)CONTACT:John Lai, CEO PetVivo Holdings, Inc. Email: info1@petvivo.com (952) 405-6216Forward-Looking commercial Statements:The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements

  • GlobeNewswire

    PetVivo Announces Notice of Allowance for United States Patent Application Enhancing the Proprietary Coverage of Kush®, a Treatment for Animal Lameness

    MINNEAPOLIS, MN, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the United States Patent and Trademark Office (USPTO) has allowed an important patent related to the Company’s proprietary biomaterial, which the company utilizes to produce its proprietary products. The broad scope of the issued claims in this patent, entitled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof,” provides tremendous proprietary protection for a broad range of proprietary products, including the product Kush, a medical device treatment for animal osteoarthritis. “Our biomaterial technology and the claims issued in this patent provides us extremely comprehensive coverage. This patent extends the scope of our patent claims thereby expanding our competitive advantage in medical devices and other therapeutics used in a multitude of treatments for pets,” noted PetVivo Chief Executive Officer, John Lai. “In addition, the claims covering our innovative biomaterials disclosed in this newly allowed patent application provides proprietary protection for our Kush™ particles used to treat animal lameness.”With this recent patent allowance by the USPTO, PetVivo’s intellectual property portfolio has grown to twenty-one allowed patents, ten of which are United States patents. PetVivo has an additional ten patent applications pending in the US and in strategic foreign countries.“It is exciting to see the ongoing expansion of our intellectual property. This expansion highlights the novelty of our biomaterials, devices and treatments including our flagship product, Kush,” commented PetVivo CEO John Lai. “We look forward to improving the quality of life for osteoarthritic dogs, horses and their respective owners with the broad commercial launch of Kush slated for later this year.”PetVivo diligently protects its proprietary technologies, including the fabricated biomaterials and their application in end products and devices. To maximize the strength and value of its intellectual property the claims generally cover the commercial devices/therapeutics, the manufacturing methods and the methods of use of PetVivo’s proprietary technology.About PetVivo Holdings, Inc.For more information about PetVivo and Kush, please contact info1@petvivo.com or visit https://petvivo.com/PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.Forward-Looking commercial Statements:The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.CONTACT: John Lai Chief Executive Officer PetVivo Holdings, Inc. Email: info1@petvivo.com Main: 952-405-6216

  • ACCESSWIRE

    Goldman Small Cap Research Issues New Sector Snapshot Featuring PetVivo Holdings, Inc.

    BALTIMORE, MD / ACCESSWIRE / July 20, 2020 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new Sector Snapshot on the Veterinary Health segment, in which PetVivo Holdings, Inc.